Collaborative Innovation in Drug Discovery

RATHNAM CHAGUTURU, PHD, is the Founder & CEO of iDDPartners, a nonprofit think-tank focused on pharmaceutical innovation. He has more than thirty years of experience in executing new lead discovery projects and forging discovery partnerships. He is the Founding President of the International Chemical Biology Society and Editor-in-Chief of Combinatorial Chemistry and High Throughput Screening. He serves on several other editorial and scientific advisory boards along with NIH Study Sections, is the recipient of several awards, and is a much sought-after speaker at major national and international conferences, passionately advocating the virtues of collaborative partnerships in addressing the pharmaceutical innovation crisis.

• Foreword xvby Ferid MuradPreface xixAbout the Book xxvAbout the Editor xxviiContributors xxixPART I: PERSPECTIVES ON COLLABORATIVE INNOVATION 1If I have seen further it is by standing on the shoulders of giants.—Isaac Newton1 PRODUCTIVE RELATIONSHIPS IN RESEARCH AND DEVELOPMENT BETWEEN GOVERNMENT, INDUSTRY, AND UNIVERSITIES 3Wyatt R. Hume2 DIVIDED WE FALL 11William B. Mattes3 INNOVATION: OPEN SOURCE AND NONPROFIT MODELS IN DRUG DISCOVERY 21James M. Shaeffer and Sarah MacDonald4 THE CHANGING FACE OF INNOVATION IN DRUG DISCOVERY 31Litao Zhang and Carl Decicco5 CURRENT TRENDS IN COLLABORATIVE DRUG DISCOVERY AND STRATEGIES TO DE-RISKPRECOMPETITIVE INITIATIVES 57Anuradha Roy and Rathnam Chaguturu6 A PERSPECTIVE ON THE EVOLUTION OF COLLABORATIVE DRUG DISCOVERY AND FUTURE CHALLENGES 75Christopher A. LipinskiPART II: GOVERNMENTAL INITIATIVES ACCELERATE PRECOMPETITIVE COLLABORATION 85Governments will always play a huge part in solving big problems. . . .They also fund basic research, which is a crucial component of the innovation that improves life for everyone. —Bill Gates7 THE VALUE OF UNIVERSITY–INDUSTRY PARTNERSHIPS 87Anthony M. Boccanfuso8 TRENDS IN THE PUBLIC SECTOR ADOPTION OF TRANSLATIONAL RESEARCH APPROACHES 99Mark A. Scheideler9 PARTNERSHIPS FOR DRUG REPOSITIONING: LESSONS FROM THE CTSA PHARMACEUTICAL ASSETS PORTAL 115Kate Marusina, Dean J. Welsch, Lynn Rose, Doug Brock, Nathan Bahr, Aaron M. Cohen, Rafael A. Gacel-Sinclair, Pakou Vang, Peter G. Ruminski, Bruce E. Bloom, Pamela Nagasawa, and Betty P. Guo10 DEVELOPMENT PROGRAMS AT THE U.S. NATIONAL CANCER INSTITUTE: USE OF PUBLIC–PRIVATE PARTNERSHIPS AS A CATALYST TO ADVANCE CANCER THERAPY 135Jason V. Cristofaro11 NONINDUSTRIAL PHARMACEUTICAL RESEARCH IN THE BRIC COUNTRIES: LESSONS FOR DRUG DISCOVERY PARTNERSHIPS WITH ACADEMIC AND GOVERNMENTAL INSTITUTIONS 159John Watson12 DEATH OF DRUGS AND REBIRTH OF HEALTH CARE: INDIAN RESPONSE TO DISCOVERY IMPASSE 173Bhushan PatwardhanPART III: A GAME CHANGER FOR AVERTING FUTURE PHARMA CLIFF 195Coming together is a beginning, staying together is progress, and working together is success. —Henry Ford13 ACCELERATING INNOVATION IN THE BIOSCIENCE REVOLUTION 197Bernard H. Munos14 VALUE-DRIVEN DRUG DEVELOPMENT: UNLOCKING THE VALUE OF YOUR PIPELINE 213Valentina Sartori, Michael Steinmann, Petra Jantzer, and Matthias Evers15 UNLOCKING THE MARKET POTENTIAL OF ACADEMIC RESEARCH 221Assem S. el Baghdady and Yasser M.S. el Baghdady16 COLLABORATIVE INNOVATION IN PHARMACEUTICAL INDUSTRY: APPROACHES AND REQUIREMENTS 255Monika Lessl and Khusru Asadullah17 CLOSE CONTACT: A COLOCATION MODEL FOR ACADEMIC–INDUSTRIAL PARTNERSHIPS IN DRUG DISCOVERY 267Peter A. Covitz and Terrence D. Ruddy18 SUCCESS FACTORS AND OBSTACLES IN ACADEMIA–INDUSTRY PARTNERSHIPS: A CASE STUDY OF A GRADUATE PROGRAM WITHIN THE BAYER–UNIVERSITY OF COLOGNE “PRIVILEGED PARTNERSHIP” 279Stefan Herzig, Marion Rozowski, and Ingo Flamme19 ACADEMIC, COMMERCIAL, AND BIODEFENSE CASE STUDIES FOR COLLABORATIVE DRUG DISCOVERY: POTENTIAL FOR DISRUPTING DRUG DISCOVERY 303Barry A. Bunin and Sean Ekins20 ACCESS PLATFORM: A STREAMLINED INTEGRATIVE PARTNERING PROCESS AT SANOFI TO COMMERCIALIZE UNIVERSITY-BASED INTELLECTUAL PROPERTY 319Paul R. Eynott and Carole Fages21 ENTREPRENEURSHIP: DRUG DISCOVERY INNOVATION AT START-UP AND MEDIUM-SIZED BIOTECHNOLOGY COMPANIES 341Allen B. Reitz and Kathleen M. Czupich22 CHEMICAL CONSULTING 355Lester A. MitscherPART IV: NONPROFITS DRIVE BENCH-TO-BEDSIDE INNOVATION 367Can’t afford to innovate? Open up! —Henry Chesbrough23 OPEN SOURCE DRUG DISCOVERY FOR NEGLECTED DISEASES 369Tonny Johnson and Sanchayita Kar24 THE MYELIN REPAIR FOUNDATION ACCELERATED RESEARCH COLLABORATIONTM MODEL: INNOVATIVE DISRUPTION IN BIOMEDICAL RESEARCH 385Gali Hagel25 FROM CATALYSIS TO MASS ACTION: THE EVOLUTION OF CHDI FOUNDATION, A DRUG-DEVELOPMENT ORGANIZATION DEVOTED TO HUNTINGTON’S DISEASE 411Allan J. Tobin26 LESSONS FROM THE PAST AS A MEANS TO THE FUTURE: INSTITUT PASTEUR AS A MODEL STRATEGY 437Spencer L. Shorte27 SEEDING OPEN INNOVATION DRUG DISCOVERY AND TRANSLATIONAL COLLABORATIONS TO LEVERAGE GOVERNMENT FUNDING: A CASE STUDY OF STRATEGIC PARTNERSHIP BETWEEN SANFORD-BURNHAM AND MAYO CLINIC 451Thomas D.Y. Chung, Sundeep Khosla, Andrew D. Badley, and Michael R. JacksonPART V: ACADEMIC SCREENING CENTERS COME OF AGE 487Open access high-throughput drug discovery in the public domain is a Mount Everest in the making. —Rathnam Chaguturu28 FINDING THE MIDDLE GROUND: DRUG DISCOVERY TECHNOLOGY IN THE ERA OF ACADEMIC SCREENING CENTERS 489Nathan S. Blow29 OPEN INNOVATION-BASED DRUG DISCOVERY IN EUROPE: SOME EXAMPLES OF NATIONAL AND TRANSNATIONAL EUROPEAN INITIATIVES INTEGRATING CHEMISTRY, BIOLOGY, AND TECHNOLOGY PLATFORMS 499Philip Gribbon30 IN SICKNESS AND IN HEALTH: A SHOTGUN MARRIAGE THAT IS FLOURISHING 517Horst Flotow and Alex Matter31 A FLEXIBLE MODEL FOR COMPOUND MANAGEMENT FACILITIES TO STIMULATE COLLABORATIONS IN THE LIFE SCIENCES 533David CampPART VI: INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER 563Everything that can be invented has been invented. —Charles Duell32 SUCCESSFUL TECHNOLOGY TRANSFER: LESSONS FROM THE TRANSLATIONAL MEDICINE RESEARCH COLLABORATION 565Assem S. el Baghdady33 CHALLENGES AND OPPORTUNITIES IN COMMERCIALIZING ACADEMIC DRUG DISCOVERIES 577Christopher Paschall34 THE PIVOTAL ROLE OF THE ACADEMIC ENTREPRENEUR AND THE ENTREPRENEURIAL UNIVERSITY IN GLOBAL LIFE SCIENCES 609Donna Marie De CarolisPART VII: THE FINAL FRONTIER 621No one can whistle a symphony; it takes a whole orchestra to play it.—Halford E. Luccock35 THE CORE MODEL: DRUG DISCOVERY AND DEVELOPMENT VIA EFFECTIVE TRANSLATIONAL SCIENCE AND PUBLIC–PRIVATE COLLABORATION 623Ibis Sánchez-Serrano36 USING MARKET-DRIVEN COLLABORATION TO ACCELERATE INNOVATION IN BIOMEDICINE 653Elizabeth Iorns37 THE COST OF TAKING EYES OFF THE TRUE END USER: FOCUS ON PATIENT NEEDS AND OUTCOMES 663Deborah E. Collyar38 TO LEASH OR UNLEASH THE POWER OF PUBLIC–PRIVATE COLLABORATION: IN HEALTH AND DISEASE 679Hakim DjaballahIndex 687